A Review of Outcomes for Stage Ta Bladder Tumors
|
|
- Juniper Dawson
- 5 years ago
- Views:
Transcription
1 AJCP /ORIGINAL ARTICLE A Review of Outcomes for Stage Ta Bladder Tumors Robin T. Vollmer, MD From the VA and Duke University Medical Centers, Durham, NC. Key Words: Urothelial tumors; Tumor grade; Outcomes; Evidence based; Survival times Am J Clin Pathol August 2016;146: DOI: /AJCP/AQW103 ABSTRACT Objectives: Using data from former reports, this study reviews and analyzes the outcomes of tumor recurrence, tumor progression, and tumor-specific survival of patients with stage Ta bladder tumors. Methods: Data were collected from 19 longitudinal studies of outcomes after the first diagnosis of tumor and collected as individual patient results, that is, as failure times from the first tumor to any of the three outcomes. Altogether, there were 14,252 patients, including 4,050 for the outcome of tumor recurrence, 2,937 for the outcome of tumor progression, and 11,595 for the outcome of disease-specific survival (some patients were available for more than one outcome). Results: In these data, the mean time to additional tumors was 7.8 years, the mean time to an invasive tumor was 19.5 years, and the mean tumor-specific survival time was 27.2 years. All three outcomes were significantly related to the 2004 World Health Organization (WHO) tumor grades. Conclusions: Although greater than 50% of those with stage Ta bladder tumors have additional bladder tumors, approximately 80% appear to follow a benign course without developing invasive tumors or dying of bladder cancer. The 2004 WHO grading scheme accounts for some but not all of the prognostic information. There has been continuing controversy about the nomenclature of noninvasive bladder tumors. Several studies have opined that some noninvasive bladder tumors may be considered benign. For example, in 1987, Jordan et al 1 wrote that the low grade lesions (usually designated transitional cell carcinoma, Grade I) are benign and should be called papillomas rather than carcinomas, a notion that was not popular. 2 Jordan et al 1 also wrote that the confusion of the risk of carcinoma with the presence of carcinoma seems to be a mind-set peculiar to the discussion of urothelial neoplasms, and in 1999, Murphy 3 wrote, Considering the accumulating evidence, the seeming reluctance of many to conclude that these low grade, noninvasive, papillary urothelial tumors are not themselves malignant is hard to fathom. In 2002, Bostwick and Mikuz 4 explained that the chief motivation for a new classification was to avoid use of the cancer for neoplasms with a low likelihood of invasion, recurrence and death. Consequently, the category of papillary urothelial neoplasm of low malignant potential in the 2004 World Health Organization (WHO) classification has become a popular way to address the issue. 5,6 Here, I review and analyze data from several previously published longitudinal studies to examine the outcomes of tumor-free survival time, time to progressive (ie, invasive) tumor, and time to tumor-specific death for stage Ta bladder tumors as well as to see how these outcomes relate to the 2004 WHO grading scheme. Materials and Methods The data for this study come from 19 previously published longitudinal studies of stage Ta bladder tumors Studies or subsets of patients with either urothelial papilloma American Society for Clinical Pathology, All rights reserved. For permissions, please journals.permissions@oup.com 215 Am J Clin Pathol 2016;146: DOI: /ajcp/aqw103
2 Vollmer /OUTCOMES FOR STAGE TA BLADDER TUMORS or urothelial carcinoma in situ were excluded, and many studies were excluded because they provided results for the combination of stage Ta and T1 tumors rather than for stage Ta alone. Studies were included only if they documented outcomes after the first episode of tumor and only if all tumors were completely removed. Data on tumor grade were included only if the 2004 WHO grading scheme was used: papillary urothelial neoplasm of low malignant potential (LMP), low-grade (LG) urothelial carcinomas, and highgrade (HG) urothelial carcinomas. The outcomes studied comprised the occurrence of additional tumors (tumor-free survival), progression to invasive tumor, and disease-specific survival. Outcomes were collected as failure times for specific patients. Two of the studies provided specific patient results. Others provided survival curves that were digitized and then used to estimate individual outcomes. For example, if the survival probability at time t is symbolized as S(t) and the survival probability after an interval of Dt is symbolized as S(t þ Dt), then the number of patients who failed (nf) in the time interval Dt can be estimated as nf ¼ na fst ðþ Stþ ð DtÞg (1) Here, na symbolizes the number of patients available at time t, and na was estimated using an exponential model as follows: na ¼ no expð b tþ (2) where no symbolizes the number of patients at the beginning of a study when t ¼ 0. The model of equation 2 was chosen because it closely fit reported numbers of patients available in five previously reported studies 15,18,22,23,26 involving collectively 4,238 patients with Ta stage bladder tumors. Figure 1 summarizes this fit by plotting the observed number of patients available at times of follow-up on the x-axis vs the number predicted by equation 2 on the y-axis. The straight line shows where points of perfect agreement should occur. Finally, the number of censored patients, nc, in the time interval Dt was estimated as follows: nc ¼ ðno RnfÞfexp ð b tþ expð b ½t þ DtŠÞg (3) Here, Rnf symbolizes the sum of patients who failed. For five of the studies, values of b were chosen to fit the tabulated data on numbers of patients followed, as demonstrated in Figure 1. For 11 studies, b was derived from either the median or mean of follow-up times for the study, because equation 2 implies that and b ¼ log ð:5þ=median time of follow-up (4) b ¼ 1=mean time of follow-up (5) No. of Patients Expected 2,000 1,500 1, For the final four studies, the value of b was imputed as the inverse of the mean of follow-up times for the studies that provided mean follow-up times. The above approach was used to derive individual patient failure times for each outcome. The primary goal was to obtain graphical comparisons as well as mean failure times for outcomes, although a secondary goal was to study the influence of the 2004 WHO grading scheme on outcomes. Altogether, the studies contributed 14,439 individual patients (see Table 1 for a summary) Because the data were in the public domain and de-identified, neither ethics approval nor informed consent was necessary or obtained. Results ,000 1,500 2,000 No. of Observed Patients Available Figure 1 Plot of the observed number of patients available at times of follow-up on the x-axis vs the number predicted by equation 2 on the y-axis. The straight line shows where points of perfect agreement should occur. Recurrence-Free Survival Figure 2 shows a Kaplan-Meier plot of the probability of being tumor free vs years of follow-up for all the patients, regardless of their tumor grade. For this analysis, there were 4,050 patients. Figure 3 shows Kaplan-Meier plots of the probability of being tumor free vs years of follow-up stratified according to the 2004 WHO grades. Further details are provided in Table 2, which includes the long-term estimate of the percentage of patients who failed (symbolized as FR). For example, overall 56% of patients had additional tumors during follow-up. In general, grade significantly affected tumor-free recurrence times (P 0by log-rank test); however, in the subset of patients with either LG or HG tumors, there was no significant difference in tumor-free survival times (P >.1 by log-rank test), and the percentage who failed for these two grades was nearly the same. 216 Am J Clin Pathol 2016;146: American Society for Clinical Pathology 216 DOI: /ajcp/aqw103
3 AJCP /ORIGINAL ARTICLE Table 1 Summary of Studies and Numbers of Patients First Author No. of Patients LMP, No. LG, No. HG, No. Anderstrom 7 77 Lutzeyer Heney Malmstrom Parmar Witjes Fleshner 13 9,786 Chen Leblanc Cheng Millan-Rodriguez Oosterhuis Herr Pich Holmang Mariappan Pan 23 1, Cao De Nunzio HG, high-grade tumors; LG, low-grade tumors; LMP, low malignant potential;, no patients with that grade were available or another grading scheme was used. Table 2 Tumor-Free Survival Times for Stage Ta Bladder Tumors 2004 WHO Grade No. of Patients Median, y Mean, y FR, % All grades a 4, LMP 419 NA LG 1, HG FR, expected long-term failure rate (ie, the percentage of patients expected to develop additional bladder tumors); HG, high-grade tumors; LG, low-grade tumors; LMP, low malignant potential; NA, time for median tumor-free survival was not reached; WHO, World Health Organization. a All grades indicates that either the 2004 WHO grading scheme was not used or that the tumor grades were not given. Progression-Free Survival Figure 4 shows a Kaplan-Meier plot of the probability of being free of invasive tumor vs years of follow-up for all patients, regardless of their tumor grade. For this analysis, there were 2,937 patients. Figure 5 shows Kaplan-Meier plots of the probability of being free of invasive tumor vs years of follow-up stratified according to the 2004 WHO grades. Further details are provided in Table 3, which includes the long-term estimate of the percentage of patients who failed (symbolized as FR). For example, overall 21% of patients had invasive tumors during follow-up. Grade significantly affected progression to invasive tumor (P 0 by log-rank test), and the percentage who eventually progressed steadily increased with tumor grade. Tumor-Specific Survival Figure 6 shows a Kaplan-Meier plot of the probability of tumor-specific survival vs years of follow-up for all the Tumor-Free Survival Figure 2 A Kaplan-Meier plot of the probability of being tumor free vs years of follow-up for all patients, regardless of their tumor grade. For this analysis, there were 4,050 patients. Tumor-Free Survival HG LG LMP Figure 3 Kaplan-Meier plots of the probability of being tumor free vs years of follow-up stratified according to the 2004 World Health Organization grades. HG, high grade; LG, low grade; LMP, papillary tumors of low malignant potential. patients, regardless of their tumor grade. For this analysis, there were 11,595 patients. Figure 7 shows Kaplan-Meier plots of the probability of tumor-specific survival vs years of follow-up stratified according to the 2004 WHO grades. Further details are provided in Table 4, which includes the long-term estimate of the percentage of patients who failed (symbolized as FR). For example, overall 18% of patients died of bladder cancer. Grade significantly affected tumor specific survival (P ¼ by log-rank test), and those with HG had the highest rate of failure. Nevertheless, there was not a significant difference in tumor-specific survival between LMP and LG tumors (P >.09 by log-rank test). American Society for Clinical Pathology Am J Clin Pathol 2016;146: DOI: /ajcp/aqw103
4 Vollmer /OUTCOMES FOR STAGE TA BLADDER TUMORS LMP Progression-Free Survival Progression-Free Survival HG LG Figure 4 A Kaplan-Meier plot of the probability of being free of invasive tumor vs years of follow-up for all the patients, regardless of their tumor grade. For this analysis, there were 2,937 patients Figure 6 A Kaplan-Meier plot of the probability of tumorspecific survival vs years of follow-up for all the patients, regardless of their tumor grade. For this analysis, there were 11,595 patients. Table 3 Progression-Free Survival Times for Stage Ta Bladder Tumors 2004 WHO Grade No. of Patients Median, y Mean, y FR, % All grades a 2,937 NA LMP 419 NA LG 966 NA HG 307 NA FR, expected long-term failure rate (ie, the percentage of patients expected to develop invasive tumors); HG, high-grade tumors; LG, low-grade tumors; LMP, low malignant potential; NA, time for median tumor-free survival was not reached; WHO, World Health Organization. a All grades indicates that either the 2004 WHO grading scheme was not used or that the tumor grades were not given Figure 5 Kaplan-Meier plots of the probability of being free of invasive tumor vs years of follow-up stratified according to the 2004 World Health Organization grades. HG, high grade; LG, low grade; LMP, papillary tumors of low malignant potential. HG LG LMP Figure 7 Kaplan-Meier plots of the probability of tumorspecific survival vs years of follow-up stratified according to the 2004 World Health Organization grades. HG, high grade; LG, low grade; LMP, papillary tumors of low malignant potential. Table 4 Tumor-Specific Survival Times for Stage Ta Bladder Tumors 2004 WHO Grade No. of Patients Median, y Mean, y FR, % All grades a 11,595 NA LMP 324 NA 3 7 LG 654 NA HG 199 NA 1 13 FR, expected long-term failure rate (ie, the percentage of patients expected to die of bladder cancer); HG, high-grade tumors; LG, low-grade tumors; LMP, low malignant potential; NA, time for median tumor-free survival was not reached; WHO, World Health Organization. a All grades indicates that either the 2004 WHO grading scheme was not used or that the tumor grades were not given. 218 Am J Clin Pathol 2016;146: American Society for Clinical Pathology 218 DOI: /ajcp/aqw103
5 AJCP /ORIGINAL ARTICLE Discussion This study uses the data from 19 prior longitudinal studies of stage Ta bladder tumors to analyze more than 14,000 patients and their outcomes. It demonstrates that greater than 50% of those with stage Ta bladder tumors have additional bladder tumors. Despite these additional tumors, approximately 80% of these patients follow a benign course without developing invasive tumors or dying of bladder cancer. This result suggests that the LMP group is not large enough to account for all the benign-behaving bladder tumors, because in six previous studies involving collectively 2,271 patients, LMP tumors composed no more than 25% (weighted mean). 21,23,27-30 Thus, the results suggest that many patients who initially have LG tumors, and perhaps some who initially have HG tumors, follow a benign course. Regarding the effects of the 2004 WHO grading scheme, the results are limited, because only a few of the 19 studies with follow-up provided the 2004 grade information. Nevertheless, the results suggest that patients with LMP tumors have on average the longest times to additional tumors, the longest times to progression, and the longest times to disease-specific death. By contrast, those with HG tumors on average experience the shortest times to additional tumors, progression, or disease-specific death. Times to outcomes for those with LG tumors vary from matching those with HG tumors, to having failure times intermediate between LMP and HG tumors, to matching those with LMP tumors. The noise in the grade effects on outcomes may be due in part to the magnitude of time lapse from the first tumor to the outcomes. For these patients, the grade of the first tumor may have less impact on their status years later. In addition, the noise in grade effects could be partly due to variance between pathologists in their use of the 2004 grading scheme. For example, in the six studies mentioned above, 21,23,27-30 the prevalence of LMP tumors ranged from 14% to 38% (P 0 by test for equality of proportions). To me, as well as to one reviewer of this article, these rates of LMP seem unusually high. The prevalence of LG tumors ranged from 44% to 63% (P 0), and the prevalence of HG tumors ranged from 16% to 30% (P 0). Such significant differences between institutions suggest that pathologists may be grading these tumors differently or that the histologic distinction between some of the grades is too subtle to reproducibly accomplish. Additional studies using the new grading scheme and patients with longer follow-up will be needed to more thoroughly examine the effects of the 2004 WHO grading scheme. Corresponding author: Robin T. Vollmer, MD, Laboratory Medicine, 113, VA Medical Center, 508 Fulton St, Durham, NC 27705; robin.vollmer@med.va.gov. References 1. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder: can biologic potential be predicted from histologic grading? Cancer. 1987;60: Eble JN, Young RH. Benign and low-grade papillary lesions of the urinary bladder: a review of the papilloma-papillary carcinoma controversy, and a report of five typical papillomas. Semin Diagn Pathol. 1989;6: Murphy WM. Bladder cancer redefined. Cancer. 1999;86: Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virch Arch. 2002;441: Johansson SL, Busch C. Papillary urothelial neoplasm of low malignant potential. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC; 2004: Amin MB, Smith SC, Reuter VE, et al. Update for the practicing pathologist: the International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer. Mod Pathol. 2015;28: Anderstrom C, Johansson S, Nilsson S. The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J Urol. 1980;124: Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982;127: Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130: Malmstrom P-U, Busch C, Norien BJ. Recurrence, progression and survival in bladder cancer. Scand J Urol Nephrol. 1987;21: Parmar MKB, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (Urological Cancer Working Party). J Urol. 1989;142: Witjes JA, Kiemeney LALM, Schaafma HE, et al. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol. 1994;73: Fleshner NE, Herr HW, Stewart AK, et al. The National Cancer Data Base report on bladder carcinoma. Cancer. 1996;78: Chen SS, Chen KK, Lin ATL, et al. The significance of tumour grade in predicting disease progression in stage Ta transitional carcinoma of the urinary bladder. Br J Urol. 1996;78: Leblanc B, Cuclose AJ, Benard F, et al. Long-term followup of initial Ta grade I transitional cell carcinoma of the bladder. J Urol. 1999;162: Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential: clinical and biologic implications. Cancer. 1999;86: Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163: American Society for Clinical Pathology Am J Clin Pathol 2016;146: DOI: /ajcp/aqw103
6 Vollmer /OUTCOMES FOR STAGE TA BLADDER TUMORS 18. Oosterhuis JWA, Schapers RFM, Jassen-heijnen MLG, et al. Mib-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 2000;88: Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000;163: Pich A, Chiusa L, Formiconi A, et al. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol. 2001;25: Holmang S, Andius P, Hedelin H, et al. Stage progression in Ta papillary tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol. 2001;165: Mariappan P, Smith G, Lamb ADG, et al. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol. 2007;177: Pan C-C, Chang Y-H, Chen K-K, et al. Prognostic significance of 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of nonmuscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol. 2010;133: Cao D, Vollmer RT, Luly J, et al. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma. Urology. 2010;76: De Nunzio C, Carbone A, Albisinni S, et al. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomized trial. World J Urol. 2011;29: Sylvester RJ, Oosterlinck W, Holman S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pta-pt1 urothelial carcinoma of bladder: which patients benefit from the instillation? Eur Urol. 2016;69: Samaratunga H, Makarov D, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology. 2002;60: Yin H, Leong AS-Y. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. Am J Clin Pathol. 2004;121: Schned AR, Andrew AS, Marsit CJ, et al. Survival following the diagnosis of noninvasive bladder cancer: WHO/ International Society of Urological Pathology versus WHO classification systems. J Urol. 2007;178: Burger M, van der Aa MNM, van Oers JMM, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol. 2008;54: Am J Clin Pathol 2016;146: American Society for Clinical Pathology 220 DOI: /ajcp/aqw103
2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections
european urology supplements 8 (2009) 453 457 available at www.sciencedirect.com journal homepage: www.europeanurology.com 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms:
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
2885 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(15): 2885-2891. doi: 10.7150/jca.20003 Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT:
More informationAP110 URINARY BLADDER BIOPSY INTERPRETATION Part 1
AP110 URINARY BLADDER BIOPSY INTERPRETATION Part 1 Mahul B. Amin, MD Director of Surgical Pathology, Emory University Hospital Professor of Pathology, Urology, Hematology & Oncology, Emory University School
More informationRESEARCH ARTICLE. Ali Koyuncuer. Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Histopathologic Evolution of Urothelial Carcinoma Recurrence in Transurethral Resection of the Urinary Bladder:35 Consecutive Cases And Literature Review Abstract Background: Urothelial
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationUrological Oncology INTRODUCTION. M Hammad Ather, Masooma Zaidi
Urological Oncology Predicting Recurrence and Progression in Non-Muscle- Invasive Bladder Cancer Using European Organization of Research and Treatment of Cancer Risk Tables M Hammad Ather, Masooma Zaidi
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationHistologic Grading of Noninvasive Papillary Urothelial Neoplasms
european urology 51 (2007) 889 898 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Bladder Cancer Histologic Grading of Noninvasive Papillary Urothelial Neoplasms Gregory
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationPatient Risk Profiles: Prognostic Factors of Recurrence and Progression
european urology supplements 5 (2006) 648 653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Patient Risk Profiles: Prognostic Factors of Recurrence and Progression
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationOriginal Article APMC-276
Original Article APMC-276 The Clinical Value of Immediate Second Transurethral Resection in Patients with High Grade Non-Muscle Inasive Bladder Cancer (HG-NMIBC) Syed Saleem Abbas Jafri, Zafar Iqbal Khan
More informationMixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome
DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti
More informationInfluence of stage discrepancy on outcome in. in patients treated with radical cystectomy.
Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationCase Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
More informationPrognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy
European Urology European Urology 45 (2004) 292 296 Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and ProgressiveTumours and Implications fortherapy Barthold Ph. Schrier a, Maarten
More informationDiagnostic algorithm for papillary urothelial tumors in the urinary bladder
Virchows Arch (2008) 452:353 362 DOI 10.1007/s00428-008-0585-x ORIGINAL ARTICLE Diagnostic algorithm for papillary urothelial tumors in the urinary bladder Jung-Weon Shim & Kang Su Cho & Young-Deuk Choi
More informationKyung Won Seo, Byung Hoon Kim, Choal Hee Park, Chun Il Kim, Hyuk Soo Chang
www.kjurology.org DOI:.4/kju..5..65 Urological Oncology The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after
More informationE arly clinical observations regarding the biology
91 REVIEW Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies R Montironi, A Lopez-Beltran, R Mazzucchelli, D G Bostwick... The classification and grading
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationAmerican Journals of Cancer Case Reports. A Rare Case of Rectal Metastasis from Sarcomatoid Variant of Urothelial Carcinoma: A Case Report
American Journals of Cancer Case Reports Lin JYJ et al. American Journals of Cancer Case Reports 2014, 3:1-5 http://ivyunion.org/index.php/ajccr Page 1 of 5 Vol 3 Article ID 20140539, 5 pages Case Report
More informationThe Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary Study
The Journal of International Medical Research 2009; 37: 1823 1830 The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette Guérin in Superficial Bladder Cancer: a Preliminary
More informationCytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis
https://doi.org/10.1186/s13104-018-3319-4 BMC Research Notes RESEARCH NOTE Open Access Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis Atif Ali
More informationUpdate on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationNon-Invasive Urothelial Neoplasms: According to the Most Recent WHO Classification
European Urology European Urology 46 (2004) 170 176 Review Non-Invasive Urothelial Neoplasms: According to the Most Recent WHO Classification Antonio Lopez-Beltran a,1, Rodolfo Montironi b,* a Department
More informationProspective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder
Original Article p53 AS A PROGNOSTIC MARKER IN BLADDER CANCER DALBAGNI et al. There have been several published reports that p53 is a useful prognostic marker for progression and survival in bladder cancer.
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationCystoscopy in children presenting with hematuria should not be overlooked
Ped Urol Case Rep 2015; 2(3):7-11 DOI: 10.14534/PUCR.2015310303 PUCR Ped Urol Case Rep PEDIATRIC UROLOGY CASE REPORTS ISSN: 2148 2969 Journal homepage: http://www.pediatricurologycasereports.com Cystoscopy
More informationValue of Immunohistochemistry in StagingT1 Urothelial Bladder Carcinoma
European Urology European Urology 42 (2002) 459±463 Value of Immunohistochemistry in StagingT1 Urothelial Bladder Carcinoma Paulette Mhawech a,*, Christophe Iselin b, Marie-FrancËoise Pelte a a Pathologie
More informationBLADDER CANCER EPIDEMIOLOGY
BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel
More informationA rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases
MOLECULAR AND CLINICAL ONCOLOGY 8: 785-790, 2018 A rational risk assessment for intravesical recurrence in primary low grade Ta bladder cancer: A retrospective analysis of 245 cases MASAKAZU AKITAKE 1,
More informationMolecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications
& 2015 USCAP, Inc. All rights reserved 0893-3952/15 $32.00 695 Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications Bas WG van
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1123 1130 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence
More informationMultiple factor analysis of metachronous upper urinary tract transitional cell carcinoma after radical cystectomy
Brazilian Journal of Medical and Biological Research (2007) 40: 979-984 Predictive factors after radical cystectomy ISSN 0100-879X 979 Multiple factor analysis of metachronous upper urinary tract transitional
More informationLong term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression
Kobayashi et al. BMC Urology 2014, 14:5 RESEARCH ARTICLE Open Access Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationmodels; Kaplan meier curves were also extrapolated for each cohort to compare disease specific and overall survival patterns.
; 21 Urological Oncology MUSCULARIS PROPRIA AND UPSTAGING OF ct1 BLADDER CANCER BADALATO ET AL. BJUI Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationRelationship of TP53 and Ki67 expression in bladder cancer under WHO 2004 classification
JBUON 2013; 18(2): 420-424 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Relationship of TP53 and Ki67 expression in bladder cancer under WHO 2004 classification Lujia Wang 1*,
More informationMaintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk Non-muscle-invasive
Jpn J Clin Oncol 2013;43(3)305 313 doi:10.1093/jjco/hys225 Advance Access Publication 9 January 2013 Maintenance Therapy with Intravesical Bacillus Calmette Guérin in Patients with Intermediate- or High-risk
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationEarly Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non Muscle-Invasive Bladder Cancer
european urology supplements 8 (2009) 458 463 available at www.sciencedirect.com journal homepage: www.europeanurology.com Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned
More informationBeware the BCG Failures: A Review of One Institution's Results
European Urology European Urology 42 (2002) 542±546 Beware the BCG Failures: A Review of One Institution's Results C. Richard W. Lockyer a,*, James E.C. Sedgwick b, David A. Gillatt a a Bristol Urological
More informationChapter 23 Cancer of the Urinary Bladder
Charles F. Lynch, Jessica A. Davila, and Charles E. Platz Introduction Cancer of the urinary bladder most commonly originates in the urothelium, the epithelium that lines the bladder. During 6, this is
More informationImpact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy
www.kjurology.org http://dx.doi.org/./kju... Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=./kju...&domain=pdf&date_stamp= Impact of Histopathological Variant on the Outcome
More informationSecond transurethral resection against Ta high grade tumor:residual location and predictive factor. A single center, retrospective study
Japanese Journal of Endourology(2018)31:108-112 Original Article CJapanese Society of Endourology 2018 Tetsuya Shindo Naotaka Nishiyama Naoya Masumori Second transurethral resection against Ta high grade
More informationImproving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression in Superficial Bladder Cancer
european urology supplements 5 (2006) 654 659 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Improving Patient Outcomes: Optimal BCG Treatment Regimen to Prevent Progression
More informationUreteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes
ORIGINAL ARTICLE Vol. 43 (x): 2017 August 8.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2017.0218 Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes Muammer
More informationClinical Implications of the 2004 WHO Histological Classification on Non-Invasive Tumours of the Urinary Bladder
eau-ebu update series 4 (2006) 83 95 available at www.sciencedirect.com journal homepage: www.europeanurology.com Clinical Implications of the 2004 WHO Histological Classification on Non-Invasive Tumours
More informationBas W.G. van Rhijn, M.D., Ph.D., F.E.B.U.*
Urologic Oncology: Seminars and Original Investigations 30 (2012) 518 523 Seminar article Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer Bas W.G. van Rhijn,
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Clinicopathological Study of Urinary Bladder Neoplasms on Trans Urethral Resected Bladder
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationEffectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up
Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 2, June: 121-126, 2007 in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up SAMIR EL-GHOBASHY, M.D.; TAREK R. EL-LEITHY,
More informationThe clinical epidemiology of superficial bladder cancer
Br. J. Cancer (1993), 67, 86-812 '." Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 67, 86-812 1993 The clinical epidemiology of superficial bladder cancer L.A.L.M. Kiemeneyl2, J.A. Witjes3, A.L.M. Verbeekl2,
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationCD 10 Expression Intensity in Various Grades and Stages of Urothelial Carcinoma of Urinary Bladder
ORIGINAL ARTICLE CD 10 Expression Intensity in Various Grades and Stages of Urothelial Carcinoma of Urinary Bladder Muhammad Atique, Muhammad Sajjad Abbasi, Shahid Jamal, Muhammad Tahir Khadim, Farhan
More informationGenerated by Foxit PDF Creator Foxit Software For evaluation only.
Tishreen University Journal for Research and Scientific Studies - Medical Sciences Series Vol. (3) No. (٣) 28 27 2 28 2 T3 T4 T2 T1 Ta TUR G3 G2 G1 * ٩ 27 2 Tishreen University Journal for Research and
More informationA t recurrence, 5 15% of TaT1 urothelial cell carcinomas
447 ORIGINAL ARTICLE Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks M G W Bol,
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationDuctal adenocarcinoma of the prostate: A clinicopathological study
20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological
More informationModelling the recurrence of bladder cancer
Modelling the recurrence of bladder cancer Gregorio Rubio 1, Cristina Santamaría 1, Belén García 1, and José Luis Pontones 2 1 Matemática multidisciplinar Universidad Politécnica Valencia (Spain) (e-mail:
More informationLymphovascular invasion predicts poor prognosis in high-grade pt1 bladder cancer patients who underwent transurethral resection in one piece
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(5) 447 452 doi: 10.1093/jjco/hyx012 Advance Access Publication Date: 10 February 2017 Original Article Original
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationPrognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors The Role of G 1
Anatomic Pathology / PROGNOSTIC FACTORS IN BLADDER CANCER Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors The Role of G 1 -S Modulators (p53, p21waf1, p27kip1,
More informationRationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm
Rationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm Eva M. Wojcik, MD Professor and Chair of Pathology Professor of Urology Loyola University, Chicago, Il Why to standardize
More informationRole of Re-Resection in Non Muscle-Invasive Bladder Cancer
Review Special Issue: Bladder Cancer TheScientificWorldJOURNAL (2011) 11, 283 288 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2011.29 Role of Re-Resection in Non Muscle-Invasive Bladder Cancer Harry W.
More informationLong-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression
BJU International (2), 85, 824±828 Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression K. ZIEGER, H. WOLF, P.R. OLSEN* and K. HéJGAARD{ Department of Urology, Aarhus
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationPercentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy
1967 Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy Liang Cheng, MD 1,2 Darrell D. Davidson, MD, PhD 1 Haiqun Lin, MD, PhD 3 Michael O. Koch, MD 2 1 Department of Pathology
More informationCritical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC
Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul Conflict of Interest No
More informationSUPERFICIAL BLADDER CANCER MANAGEMENT
A CME Webcast/TELECONFERENCE Case by Case: CRITICAL ISSUES IN SUPERFICIAL BLADDER CANCER MANAGEMENT An Interactive Case Format with Instant Audience Polling APRIL-MAY 2005 CME Program Slide Book Sponsored
More informationMaintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer
710 Maintenance Bacillus Calmette-Guerin in High-Risk Nonmuscle-Invasive Bladder Cancer How Much Is Enough? Marc Decobert, PhD Helène LaRue, PhD François Harel, MSc François Meyer, MD Yves Fradet, MD Louis
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationHow Many Diseases in Carcinoma in situ?
How Many Diseases in Carcinoma in situ? Eva Compérat La Pitié Salpêtrière Assistance Publique Université Pierre et Marie Curie, Paris VI Carcinogenesis of Bladder Cancer (BC) BC is a panurothelial disease
More informationUrothelial Inverted Papilloma of the Lower Urinary Tract A Benign Lesion or a Precursor of Malignancy?
Urol Sci 2011;22(2):70 74 ORIGINAL ARTICLE Urothelial Inverted Papilloma of the Lower Urinary Tract A Benign Lesion or a Precursor of Malignancy? Yi-Te Chiang, Junne-Yih Kuo*, Kuang-Kuo Chen, Yen-Hwa Chang,
More informationNatural History, Recurrence, and Progression in Superficial Bladder Cancer
Review Article Superficial Bladder Cancer TheScientificWorldJOURNAL (2006) 6, 2617 2625 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2006.404 Natural History, Recurrence, and Progression in Superficial
More informationAP Slide Seminar: Tumors and Tumor-like Lesions of the Urinary Bladder. David Grignon MD, FASCP
5 2011 AP Slide Seminar: Tumors and Tumor-like Lesions of the Urinary Bladder David Grignon MD, FASCP 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe, Ste. 1600 Chicago,
More informationDisclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More information2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT
2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT 2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE AUTHORS : PROSTATE CHAPTER
More informationProtocol for the Examination of Cystectomy Specimens From Patients With Carcinoma of the Urinary Bladder
Protocol for the Examination of Cystectomy Specimens From Patients With Carcinoma of the Urinary Bladder Version: UrinaryBladder 4.0.1.1 Protocol Posting Date: February 2019 CAP Laboratory Accreditation
More informationReview Article. Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
Review Article Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer Ashish M. Kamat,*, J. Alfred Witjes, Maurizio Brausi, Mark Soloway,jj Donald Lamm, Raj Persad, Roger
More informationFrequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience
2nd Annual Surgical Meeting 2016 S-125 UROLOGY ORIGINAL ARTICLE Frequency and predictors of recurrence of bladder tumour on first check cystoscopy a tertiary care hospital experience Muhammad Farhan, Syed
More informationHarry W. Herr and S. Machele Donat Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Miscellaneous QUALITY CONTROL IN TRANSURETHRAL RESECTION OF BLADDER TUMOURS HERR and DONAT BJUI BJU INTERNATIONAL Quality control in transurethral resection
More informationApplication of Urovision FISH testing for diagnosis of bladder cancer
Application of Urovision FISH testing for diagnosis of bladder cancer Eva M. Wojcik, MD Chair and Professor of Pathology and Urology Loyola University, Chicago, USA Bladder cancer - current status ~ 76,900
More information비뇨병리연구회공청회 조남훈 연세대학교병리학교실
비뇨병리연구회공청회 조남훈 연세대학교병리학교실 종양분류코드 - 방광암 표재성방광암 근층비침윤암 (Ta, Tis/ T1) 종양분류코드 진단서 ICD vs. ICO 사보험지급기준 중증질환분류 암등록사업 공보험 80-90% 지급기준 0 기암 -pta, ptis 특이한유형 면역 / 항암치료필요 재발과병기진행 다발성여부 진단확정주체 병리진단서 임상소견서 의무기록사 종양분류코드의변천사
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationPathology review impacts clinical management of patients with T1 T2 bladder cancer
Original research Pathology review impacts clinical management of patients with T1 T2 bladder cancer Samer L. Traboulsi, MD 1 ; Fadi Brimo, MD, FRCP(C) 2 ; Yutong Yang, MD 2 ; Chelsea Maedler, MD 2 ; Noémie
More informationTUR-BT : transurethral resection of bladder tumor. 95 transitional cell carcinoma : Cytokeratin ; CK 8 11nm kD CK 1 8
Clinical evaluation of total amount of Urinary cytokeratin 8 and cytokeratin 18 measurement for detection of transitional cell carcinoma of the bladder. Kyoko ARAI Mikihiko HONDA Ken-Ichiro YOSHIDA 95transitional
More information+ use molecular testing to help drive my patients treatment plans.
+ use molecular testing to help drive my patients treatment plans. Xpert Bladder Cancer Detection & Xpert Bladder Cancer Monitor In Vitro Diagnostic Medical Device Not all tests available in all countries.
More informationManagement of Superficial Bladder Cancer Douglas S. Scherr, M.D.
Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationEfficacy and Safety of Hexaminolevulinate Fluorescence Cystoscopy in the Diagnosis of Bladder Cancer
www.kjurology.org http://dx.doi.org/.4/kju..3..8 Urological Oncology Efficacy and Safety of Hexaminolevulinate Fluorescence Cystoscopy in the Diagnosis of Bladder Cancer Jae Seung Lee, Seo Yeon Lee, Woo
More information